Abstract:An increase in the occurrence of fungal infections throughout the world, as well as the rise of novel fungal strains and antifungal resistance to commercially available drugs, suggests that new therapeutic choices for fungal infections are needed. The purpose of this research was to find new antifungal candidates or leads of secondary metabolites derived from natural sources that could effectively inhibit the enzymatic activity of Candida albicans lanosterol 14-alpha demethylase (CYP51) while also having good pharmacokinetics. In silico prediction of the drug-likeness, chemo-informatics and enzyme inhibition indicate that the 46 compounds derived from fungi, sponges, plants, bacteria and algae sources have a high novelty to meet all five requirements of Lipinski's rules and impede enzymatic function. Among the 15 candidate molecules with strong binding affinity to CYP51 investigated by molecular docking simulation, didymellamide A-E compounds demonstrated the strongest binding energy against the target protein at -11.14, -11.46, -11.98, -11.98, and -11.50 kcal/mol, respectively. Didymellamide molecules bind to comparable active pocket sites of antifungal ketoconazole and itraconazole medicines by hydrogen bonds forming to Tyr132, Ser378, Met508, His377 and Ser507, and hydrophobic interactions with HEM601 molecule. The stability of the CYP51-ligand complexes was further investigated using molecular dynamics simulations that took into account different geometric features and computed binding free energy. Using the pkCSM ADMET descriptors tool, several pharmacokinetic characteristics and the toxicity of candidate compounds were assessed. The findings of this study revealed that didymellamides could be a promising inhibitor against these CYP51 protein. However, there is still a need for further in vivo and in vitro studies to support these findings.

Comparison and analysis of the structures and binding modes of antifungal SE and CYP51 inhibitors

Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.

Design, Synthesis and Bioactivity Evaluation of Novel Arylalkene-Amide Derivatives As Dual-Target Antifungal Inhibitors

Structure-based Virtual Screening and ADME/T-based Prediction Analysis for the Discovery of Novel Antifungal CYP51 Inhibitors.

Novel Naphthylamide Derivatives As Dual-Target Antifungal Inhibitors: Design, Synthesis and Biological Evaluation.

Construction and activity evaluation of novel dual-target (SE/CYP51) anti-fungal agents containing amide naphthyl structure

The discovery of novel antifungal phenylpyridines derivatives based on CYP53 binding model

Potent arylamide derivatives as dual-target antifungal agents: Design, synthesis, biological evaluation, and molecular docking studies

Homology Modeling, Molecular Docking and Spectra Assay Studies of Sterol 14Α-Demethylase from Penicillium Digitatum

Construction and Activity Evaluation of Novel Benzodioxane Derivatives As Dual-Target Antifungal Inhibitors.

Structure-Based Rational Screening of Novel Hit Compounds with Structural Diversity for Cytochrome P450 Sterol 14α-Demethylase from Penicillium digitatum.

Homology modeling of lanosterol 14alpha-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate Interactions.

Homology Modeling of Lanosterol 14Α-Demethylase Ofcandida Albicansandaspergillus Fumigatusand Insights into the Enzyme-Substrate Interactions

Homology model, molecular dynamics simulation and novel pyrazole analogs design of Candida albicans CYP450 lanosterol 14 α-demethylase, a target enzyme for antifungal therapy

In silico prediction of Antifungal compounds from Natural sources towards Lanosterol 14-alpha demethylase (CYP51) using Molecular docking and Molecular dynamic simulation

Improved model of lanosterol 14alpha-demethylase by ligand-supported homology modeling: validation by virtual screening and azole optimization.

Potential dual inhibition of SE and CYP51 by eugenol conferring inhibition of Candida albicans: Computationally curated study with experimental validation

Discovery of Novel α,β-Unsaturated Amide Derivatives as Candidate Antifungals to Overcome Fungal Resistance

Design, Synthesis, and Biological Evaluation of Dual-Target COX-2/CYP51 Inhibitors for the Treatment of Fungal Infectious Diseases.

The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors

Three-Dimensional Model of Lanosterol 14Α-Demethylase from Cryptococcus Neoformans : Active-Site Characterization and Insights into Azole Binding